Ian Catlett

Ian Catlett is an accomplished biomedical professional with extensive experience in translational science and biomarker research. Currently serving as Executive Director and Translational Science Lead at Incyte since April 2024, Ian previously held a significant role at Bristol Myers Squibb from March 2016 to May 2024, where responsibilities included leading Translational Medicine for Deucravacitinib and overseeing Dermatology & Rheumatology therapeutic areas. Ian's earlier career at Bristol-Myers Squibb involved positions such as Director of Clinical Biomarkers and Principal Scientist, as well as a Senior Research Investigator. Prior to this, Ian worked at Vertex Pharmaceuticals in various research roles focused on biomarker development. Academic qualifications include a Ph.D. in Microbiology and Immunology from UC San Diego and a B.S. in Crop and Soil Environmental Sciences from Virginia Tech.